版本:
中国

BRIEF-Novartis says Kisqali data reinforce use in breast cancer

June 2 Novartis Ag

* Novartis presents updated data that reinforce the efficacy and safety of Kisqali (ribociclib) plus letrozole as a first-line option for hr+/her2- advanced or metastatic breast cancer

* Says Kisqali plus letrozole demonstrated median progression-free survival (PFS) of 25.3 months compared to 16.0 months for letrozole alone

* Says patients on Kisqali plus letrozole maintained overall health-related quality of life compared to those treated with letrozole alone, and no new safety concerns have been identified Source text for Eikon: [here ]

Further company coverage: (Reporting by John Miller)

我们的标准: 汤森路透“信任原则

更多 瑞士市场报道

热门文章

编辑推荐

文章推荐